(0.04%) 5 101.74 points
(0.22%) 38 323 points
(0.03%) 15 932 points
(-1.31%) $82.75
(6.34%) $2.05
(0.06%) $2 348.70
(-0.21%) $27.48
(3.83%) $957.40
(-0.19%) $0.933
(-0.29%) $10.99
(-0.52%) $0.796
(1.75%) $93.48
@ $1.954
Utstedt: 14 feb 2024 @ 15:32
Avkastning: -26.82%
Forrige signal: feb 7 - 22:00
Forrige signal:
Avkastning: 1.24 %
Live Chart Being Loaded With Signals
Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers...
Stats | |
---|---|
Dagens volum | 313 107 |
Gjennomsnittsvolum | 430 161 |
Markedsverdi | 50.03M |
EPS | $0 ( 2024-04-04 ) |
Neste inntjeningsdato | ( $-0.370 ) 2024-05-20 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.450 |
ATR14 | $0.00300 (0.21%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-20 | Fortress Biotech, Inc. | Buy | 193 905 | COMMON STOCK, PAR VALUE $0.0001 |
2024-03-12 | Amit Sharma | Sell | 0 | Common Stock (Restricted) |
2024-02-28 | Oliviero James F Iii | Sell | 5 894 | COMMON STOCK |
2024-02-28 | Oliviero James F Iii | Sell | 9 056 | COMMON STOCK |
2024-02-28 | Gray William Garrett | Sell | 2 035 | Common Stock |
INSIDER POWER |
---|
82.65 |
Last 98 transactions |
Buy: 5 337 828 | Sell: 1 367 663 |
Volum Korrelasjon
Checkpoint Therapeutics Korrelasjon
10 Mest positive korrelasjoner | |
---|---|
RMRM | 0.94 |
TLGT | 0.938 |
SVAC | 0.937 |
AGFY | 0.934 |
PAIC | 0.934 |
CCCC | 0.931 |
ALT | 0.931 |
JOAN | 0.93 |
VERU | 0.928 |
EYEG | 0.922 |
10 Mest negative korrelasjoner | |
---|---|
NETE | -0.95 |
MMAC | -0.934 |
STAY | -0.927 |
BNIXU | -0.92 |
CCRC | -0.92 |
NVCN | -0.912 |
DSPG | -0.911 |
XM | -0.909 |
FEXD | -0.901 |
AVEO | -0.896 |
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Checkpoint Therapeutics Korrelasjon - Valuta/Råvare
Checkpoint Therapeutics Økonomi
Annual | 2023 |
Omsetning: | $103 000 |
Bruttogevinst: | $-43.46M (-42 197.09 %) |
EPS: | $-2.77 |
FY | 2023 |
Omsetning: | $103 000 |
Bruttogevinst: | $-43.46M (-42 197.09 %) |
EPS: | $-2.77 |
FY | 2022 |
Omsetning: | $192 000 |
Bruttogevinst: | $-49.63M (-25 850.52 %) |
EPS: | $-7.57 |
FY | 2021 |
Omsetning: | $0.00 |
Bruttogevinst: | $0.00 (0.00 %) |
EPS: | $-10.15 |
Financial Reports:
No articles found.
Checkpoint Therapeutics
Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-1 and B7.1 receptors; and CK-302, a human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells. It is also developing Olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a treatment for patients with EGFR mutation-positive non-small cell lung cancer; CK-103, a selective and potent small molecule inhibitor of bromodomain and extra-terminal bromodomains; and anti-carbonic anhydrase IX (CAIX) antibody, a fully human preclinical antibody to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has collaboration agreements with TG Therapeutics, Inc. to develop and commercialize certain assets in connection with its licenses in the field of hematological malignancies. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.